HC Wainwright Predicts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Fractyl Health in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of $0.79 for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Fractyl Health Stock Performance

Shares of GUTS opened at $2.18 on Tuesday. The stock has a market capitalization of $298.75 million, a P/E ratio of -0.95 and a beta of 1.62. Fractyl Health has a 1 year low of $0.82 and a 1 year high of $3.03. The company’s fifty day moving average is $1.99 and its two-hundred day moving average is $1.52.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently modified their holdings of GUTS. Nantahala Capital Management LLC acquired a new position in Fractyl Health in the third quarter valued at approximately $19,298,000. Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health during the third quarter valued at $8,981,000. Rosalind Advisors Inc. bought a new stake in shares of Fractyl Health during the 3rd quarter worth about $7,950,000. Woodline Partners LP raised its holdings in Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after purchasing an additional 4,908,693 shares in the last quarter. Finally, General Catalyst Group Management LLC bought a new position in Fractyl Health during the second quarter valued at about $7,912,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.